![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 22 of 22. This is the beginning of the thread.
Posted by rjlockhart on February 28, 2007, at 14:47:43
Listen i had a bad problem with, well i took adderall for 10 years, and then the last 3 years i started to abuse it, i noticed its increase in effect, well my mom, i understand never wants me to go back on a stimulant, ever again.
That is probaly going to be so, because she is very strict about it now, i cant be on anything that she thinks that will cause the effect of stimulants, plus abuse.
She blew things out of preprortion saying i could of been dead, or in jail, please, well the reason is because she had a abuse problem with desoxyn in 1970's! That why she thinks the way she is thinking.
But she has no problem with me taking Xanax. Isnt that wierd.
I cant be on stimulant and live with her she will just go nuts. So i have to take it easy, get over it, and move on.
But what about thsi new medication just out of curiosity?
Rj
Posted by notfred on February 28, 2007, at 15:33:15
In reply to Question about if the new ADHD medication, posted by rjlockhart on February 28, 2007, at 14:47:43
>
> But what about thsi new medication just out of curiosity?
>
> Rj
It is amphetamine.
Posted by med_empowered on February 28, 2007, at 15:33:30
In reply to Question about if the new ADHD medication, posted by rjlockhart on February 28, 2007, at 14:47:43
I think you should try moving out or something. Prescribing the new dexedrine would be up to your doc, but there is a reduced abuse potential.
Good luck.
Posted by rjlockhart on February 28, 2007, at 19:14:06
In reply to Question about if the new ADHD medication, posted by rjlockhart on February 28, 2007, at 14:47:43
Well
I will probaly not ever go, well for the next 5 years go on any amphetamine.
So i'll just have to go on with life.
Notfred, are you on any psychostimulant?
Posted by dbc on February 28, 2007, at 20:57:35
In reply to Re: Question about if the new ADHD medication, posted by rjlockhart on February 28, 2007, at 19:14:06
Its just dexedrine thats been altered to keep kids from snorting it.
Posted by laima on February 28, 2007, at 22:57:34
In reply to Question about if the new ADHD medication, posted by rjlockhart on February 28, 2007, at 14:47:43
Are we all thinking of the same med? This one is specifically meant to be not so abuseable-an amphetamine that's abit different. Here's a copy of a recent post from right here on babble:Vyvanse: new Adhd treatment
Posted by Joe Bloe on February 27, 2007, at 17:09:21
The FDA approved this new d-amphetamine based treatment for Adhd, called Vyvanse. It seems that Shire bought New River, the company that developed the drug, outright. Here is the important information from the Shire website about its reported action, followed by the link to wikipedia. It would nice to see a trial of this next to dexedrine alone.
(Thanks Laima for mentioning this in an above thread)
"New River developed VYVANSE as a new ADHD medication designed to provide lower potential for abuse, in which d-amphetamine is covalently linked to l-lysine, a naturally occurring amino acid. The combination is rapidly absorbed from the gastrointestinal tract and converted to d-amphetamine, which is responsible for VYVANSE’s activity."
http://en.wikipedia.org/wiki/Lisdexamfetamine
And here is a press release from Shire's site:http://www.shire.com/shire/NewsAndMedia/PressReleases/showShirePress.jsp?ref=715&tn=3&m1=8&m2=13
Press Releases
FDA Approval of VYVANSE™ as a Novel Treatment for ADHD23 Feb 2007 - Basingstoke, U.K., Philadelphia, PA and Radford, VA – FEBRUARY 23, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
On February 20, 2007 Shire and New River announced an agreement whereby Shire will acquire New River for approximately $2.6 billion in an all cash transaction unanimously recommended by the Boards of both companies. The transaction is the subject of another press release issued February 20, 2007.
VYVANSE is a prodrug that is therapeutically inactive until metabolized in the body. In clinical studies designed to measure duration of effect, VYVANSE provided significant efficacy compared to placebo for a full treatment day, up through and including 6:00 pm. Furthermore, when VYVANSE was administered orally and intravenously in two clinical human drug abuse studies, VYVANSE produced subjective responses on a scale of “Drug Liking Effects” (DLE) that were less than d-amphetamine at equivalent doses. DLE is used in clinical abuse studies to measure relative preference among known substance abusers.
“The FDA approval of VYVANSE is exciting news for Shire as well as for patients, their families, and healthcare providers as it’s an important, novel approach for the treatment of ADHD,” said Matthew Emmens, Shire Chief Executive Officer. “The label we received with the approval letter includes information about the extended duration of effect and abuse-related drug liking characteristics of VYVANSE which illustrate benefits that differentiate this compound from other ADHD medicines. The addition of VYVANSE to our ADHD portfolio reaffirms Shire’s commitment to continue to address unmet medical needs and advance the science of ADHD treatment. Beginning with product launch in Q2 2007, Shire will make VYVANSE our top promotional priority within our ADHD portfolio.”
Randal J. Kirk, New River’s Chairman and Chief Executive Officer, remarked, “VYVANSE’s approval signals a new era in the treatment of ADHD. Upon product launch, patients will have a novel treatment option combining the effectiveness of a stimulant – long considered the gold standard in ADHD medicines – with other potential benefits.”
The FDA has proposed that VYVANSE be classified as a Schedule II controlled substance. This proposal was submitted to and accepted by the U.S. Drug Enforcement Administration (DEA). A final scheduling decision is expected from the DEA following a 30-day period for public comment. Once VYVANSE receives final scheduling designation, the label will be available. Pending final scheduling designation, product launch is anticipated in Q2 2007. VYVANSE will be available in three dosage strengths: 30 mg, 50 mg and 70 mg, all indicated for once-daily dosing.1
New River developed VYVANSE as a new ADHD medication designed to provide lower potential for abuse, in which d-amphetamine is covalently linked to l-lysine, a naturally occurring amino acid. The combination is rapidly absorbed from the gastrointestinal tract and converted to d-amphetamine, which is responsible for VYVANSE’s activity.
Joseph Biederman, MD, director of Pediatric Psychopharmacology at Massachusetts General Hospital, was lead investigator on the pivotal clinical studies testing lisdexamfetamine dimesylate for the treatment of ADHD. These large multi-site studies showed that the drug significantly reduced ADHD symptoms throughout the day with a predictable tolerability profile. “Our studies showed that this next-generation stimulant medication's unique chemical profile offers an option for physicians and their patients in the treatment of ADHD, with outstanding efficacy and duration of action” said Dr. Biederman.
Additional information about VYVANSE and other Shire treatments for ADHD is available at www.ShireADHDTreatments.com.
VYVANSE Significantly Controls ADHD Symptoms
Data from phase II and phase III clinical trials demonstrated statistically significant improvements in ADHD symptoms for patients aged 6 to 12 years treated with VYVANSE compared to patients treated with placebo. These studies demonstrated that all doses of VYVANSE (30 mg, 50 mg and 70 mg) provided significant efficacy at all time points tested, including 6pm.2In the phase II, analog classroom study, patients demonstrated significantly improved behavior when receiving either VYVANSE or ADDERALL XR® (mixed salts of a single-entity amphetamine product) as measured by the Swanson, Kotkin, Agler, M. Flynn and Pelham (SKAMP) deportment rating scale, a standardized, validated classroom assessment tool used for evaluating the behavioral symptoms of ADHD.3 Both treatments resulted in significantly improved behavior versus a placebo (P <.0001, for both).4 Patients also demonstrated significantly improved academic productivity with both treatments, compared to placebo (P <.0001 for both medications) as measured by Permanent Product Measure of Performance (PERMP), an age-adjusted collection of math problems that measures a child’s ability to pay attention and stay on task as demonstrated by an increase in the number of attempted and successfully completed problems.4
In the phase III, randomized, double-blind placebo-controlled study, all three doses of VYVANSE demonstrated significant improvements in ADHD Rating Scale (ADHD-RS-IV) scores compared with placebo (P <.0001) after four weeks of once-daily treatment. 5 ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD in children and for assessing their response to treatment.6,7 This scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the APA’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision®, a publication of the American Psychiatric Association. 8
Additionally, in a study presented in October at a major scientific meeting, VYVANSE yielded a 60 percent improvement in the primary rating scale scores for symptoms of ADHD in children aged 6 to 12 years who received six months of treatment in an open-label phase III study. Results also demonstrated that at 6 months, 95 percent of children taking VYVANSE produced a “much improved” or “very much improved” rating on the Clinical Global Impressions – Improvement score.9
About VYVANSE and ADDERALL XR
Tell your doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform your doctor immediately if you or your child develops symptoms that suggest heart problems, such as chest pain or fainting.VYVANSE or Adderall XR should not be taken by patients who have advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.
Tell your doctor before using VYVANSE or Adderall XR if you or your child are being treated for or have symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; have abnormal thoughts or visions, hear abnormal sounds, or have been diagnosed with psychosis; have had seizures or abnormal EEGs; have or have had high blood pressure; exhibit aggressive behavior or hostility. Tell your doctor immediately if any of these conditions or symptoms develop while using VYVANSE or Adderall XR.
Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.
VYVANSE and Adderall XR were generally well tolerated in clinical studies. The most common side effects in studies of VYVANSE included: children - decreased appetite, difficulty falling asleep, stomachache, and irritability. The most common side effects in studies of Adderall XR included: children - decreased appetite, difficulty falling asleep, stomachache, and emotional lability; adolescents - loss of appetite, difficulty falling asleep, stomachache, and weight loss; adults - dry mouth, loss of appetite, difficulty falling asleep, headache, and weight loss.
Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics and Tourette’s syndrome have been associated with use of drugs of this type. Tell your doctor if you or your child have blurred vision while taking VYVANSE or Adderall XR.
The Collaboration Agreement
In January 2005, New River Pharmaceuticals signed a collaborative agreement with Shire to develop and commercialize VYVANSE. Details on the collaboration agreement are available in previous filings with the U.S. Securities and Exchange Commission.Planned Acquisition Additional Information
The tender offer described in this press release has not yet commenced, and this press release is neither an offer to purchase nor a solicitation of an offer to sell New River common stock. Investors and security holders are urged to read both the tender offer statement and the solicitation/recommendation statement regarding the tender offer described in this report when they become available because they will contain important information. The tender offer statement will be filed by a subsidiary of Shire with the Securities and Exchange Commission (SEC), and the solicitation/recommendation statement will be filed by New River with the SEC. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed by Shire or New River with the SEC at the website maintained by the SEC at www.sec.gov. The tender offer statement and related materials may be obtained for free by directing such requests to Shire at Hampshire International Business Park, Chineham, Basingstoke, Hampshire, England, RG24 8EP, attention: Investor Relations. The solicitation/recommendation statement and such other documents may be obtained by directing such requests to New River at 1881 Grove Avenue, Radford, Virginia 24141, attention: Director of Corporate Communications.
For further information on Shire please contact:
Investor Relations Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Eric Rojas (North America) +1 484 595 8252
Media Jessica Mann (Rest of the World) +44 1256 894 280
Matthew Cabrey (North America) +1 484 595 8248
For further information on New River please contact:
The Ruth Group
John Quirk (investors)
646-536-7029
jquirk@theruthgroup.comZack Kubow (media)
646-536-7020
zkubow@theruthgroup.com
About ADHD
Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). 10 ADHD is one of the most common psychiatric disorders in children and adolescents. 11 ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development.8 To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; at least six of nine symptoms of hyperactivity/impulsivity; the onset of such symptoms before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning.8Although there is no “cure” for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.12
New River
New River Pharmaceuticals Inc. is a specialty pharmaceutical company developing novel pharmaceuticals that are generational improvements of widely prescribed drugs in large and growing markets. For further information on New River, please visit the Company's Web site at http://www.nrpharma.com.
“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995This press release contains certain forward-looking information that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historical facts. Words such as “expect(s),” “feel(s),” “believe(s),” “will,” “may,” “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of New River Pharmaceuticals, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: those discussed and identified in the New River Pharmaceuticals Inc. annual report on Form 10-K, filed with the SEC on March 15, 2006, as well as other public filings with the SEC; the timing, progress and likelihood of success of our product research and development programs; the timing and status of our preclinical and clinical development of potential drugs; the likelihood of success of our drug products in clinical trials and the regulatory approval process; our drug products’ efficacy, abuse and tamper resistance, resistance to intravenous abuse, onset and duration of drug action, ability to provide protection from overdose, ability to improve patients’ symptoms, incidence of adverse events, ability to reduce opioid tolerance, ability to reduce therapeutic variability, and ability to reduce the risks associated with certain therapies; the ability to develop, manufacture, launch and market our drug products; our projections for future revenues, profitability and ability to achieve certain threshold sales targets; our estimates regarding our capital requirements and our needs for additional financing; the likelihood of obtaining favorable scheduling and labeling of our drug products; the likelihood of regulatory approval under the Federal Food, Drug, and Cosmetic Act without having to conduct long and costly trials to generate all of the data which are often required in connection with a traditional new chemical entity; our ability to develop safer and improved versions of widely prescribed drugs using our Carrierwave (TM) technology; our success in developing our own sales and marketing capabilities for our lead product candidate; and our ability to obtain favorable patent claims. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. New River Pharmaceuticals does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in New River Pharmaceuticals’ annual report on Form 10-K, filed with the SEC on March 15, 2006, as well as other public filings with the SEC.
Shire plc
Shire’s strategic goal is to become the leading specialty pharmaceutical company that
focuses on meeting the needs of the specialist physician. Shire focuses its business on
attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT),
gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD), SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire’s planned acquisition of New River Pharmaceuticals announced February 20, 2007; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2005.
# # #
1 data on file
2 New River Pharmaceuticals Inc. CONFIDENTIAL CLINICAL STUDY REPORT PROTOCOL NO.; LDX.301 “A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of LDX in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD),” Final (4.0), 02 November 2005.
3 Wigal SB, Gupta S, Guinta S, Swanson JM. Reliability and Validity of the SKAMP Rating Scale in a Laboratory School Setting. Psychopharmacol Bull. 1998l 34 (1): 47-53.
4 “Improvements in Symptoms of Attention-Deficit/Hyperactivity Disorder in School-aged Children with Lisdexamfetamine (NRP104) and Mixed Amphetamine Salts, Extended-Release Versus Placebo,” presented at the American Psychiatric Association, Toronto, Ontario, Canada, May 24, 2006.
5 “Efficacy and Safety of Lisdexamfetamine (NRP104) in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD),” presented at the American Psychiatric Association, Toronto, Ontario, Canada, May 24, 2006.
6 DuPaul G. Parent and Teacher Ratings of ADHD Symptoms: Psychometric Properties in a Community-Based Sample. Journal of Clinical Child Psychology. 1991; 20(3): 245-53.
7 Collett BR, Ohan JL, Meyers KM. Ten Year Review of Rating Scales. V: Scales Assessing Attention-Deficit/Hyperactivity Disorder. Journal of American Academic Child Adolescent Psychiatry. 2003; 42(9): 1015-37.
8 Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition, Text Revision. DSM-TR-IV®. Washington, DC: American Psychiatric Association; 2000: 85.
9 Childress AC, Krishnan S, McGough JJ, Findling RL. Interim Analysis of a Long-Term, Open-Label, Single-Arm Study of Lisdexamfetamine (LDX), an Amphetamine Prodrug, in children with ADHD. American Academy of Child and Adolescent Psychiatry Annual Meeting; 2006 Oct. 27; San Diego, CA: American Academy of Child and Adolescent Psychiatry; 2006.
10 Mental health in the United States: Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder, United States, 2003. MMWR, September 2, 2005;54(34):842-847. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5434a2.htm. Accessed September 27, 2005.
11 “Introduction,” Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consensus Statement 1998 Nov 16-18; 16(2): 1-37. Available at: http://consensus.nih.gov/cons/110/110_statement.htm#0_Abstract. Accessed on June 8, 2005.
12 Baumgartel A, et al. Practice guideline for the diagnosis and management of attention deficit hyperactivity disorder. Ambulatory Child Health. 1998;4:51.
Posted by notfred on February 28, 2007, at 23:15:23
In reply to Re: Question about if the new ADHD medication » rjlockhart, posted by laima on February 28, 2007, at 22:57:34
>
> Are we all thinking of the same med?
Yes:The FDA has proposed that VYVANSE be classified as a Schedule II controlled substance.
Posted by laima on February 28, 2007, at 23:40:58
In reply to Re: Question about if the new ADHD medication, posted by notfred on February 28, 2007, at 23:15:23
Check out the wikipedia article. There seems to be some belief that it's actually not exactly dexedrine, and they also say it may be a good option for people with a prior history of stimulant abuse. I couldn't find it, but a while back there was a thread on babble in which someone posted that they heard euphoric effects were at an absolute minimum- which to me is interesting, as dexedrine has a euphoria-potential reputation.I also found this:
http://www.stayhealthynews.com/HealthTopStories/id_56753/Shire said it tried to limit the drug's potential for misuse. It tested the drug on adults with a history of abusing stimulants to assess its "likeability." Results suggest the drug delays the onset and limits the intensity of amphetamine-like effects, the company said.
Vyvanse works by gradually releasing its active ingredient, d-amphetamine, after the drug has been swallowed and comes into contact with enzymes in the digestive tract.
Unless it's swallowed, Vyvanse remains inactive. Shire believes that will curtail its potential for abuse by users who snort or inject crushed pills.
Posted by Joe Bloe on March 1, 2007, at 0:22:27
In reply to Re: Question about if the new ADHD medication » notfred, posted by laima on February 28, 2007, at 23:40:58
It's too bad this drug will be Schedule II, even with its supposed lower abuse potential. If it really does have a lower potential for abuse, then why not make picking it up at the pharmacy a little easier? It would be nice to go to the pharmacy without feeling like a criminal.
Posted by notfred on March 1, 2007, at 8:06:24
In reply to Re: Question about if the new ADHD medication » notfred, posted by laima on February 28, 2007, at 23:40:58
dexadrine is d-amphetamine.
Posted by laima on March 1, 2007, at 9:42:49
In reply to Re: Vyvanse - still schedule II, posted by Joe Bloe on March 1, 2007, at 0:22:27
Yes, from what I gathered from the news and business reports online, the fda simply decided an amphetamine is an amphetamine, no matter how altered, and so it's going to be schedule 2 just like all the other amphetamines. They wanted more proof, more absolute irrefutable proof that no way on earth could anyone ever ever abuse it- and per common sense that would be awfully hard to guarentee, you know? And the developer doesn't claim "never abuseable"- they claim "much less abuseable"- something like that. "Less desireable effects, less appealing to former abusers of amphetamine", something like that. (Anyone interested in their precisely exact wording can refer to their press releases, etc.) But it does sound that there was some debate or speculation about this in the industry before the decision was made-some people feeling it's a mistake, others sticking to the line.
Meanwhile, it looked like Shire is listing at least two other new meds in development for ADHD- they only have numbers, not even names yet, and are listed under "research and development" on their site. No info on what they are supposed to do.
> It's too bad this drug will be Schedule II, even with its supposed lower abuse potential. If it really does have a lower potential for abuse, then why not make picking it up at the pharmacy a little easier? It would be nice to go to the pharmacy without feeling like a criminal.
Posted by notfred on March 1, 2007, at 10:01:27
In reply to Re: Question about if the new ADHD medication, posted by rjlockhart on February 28, 2007, at 19:14:06
> Notfred, are you on any psychostimulant?
>
>In the past decades, yes, all of them except Cylert.
Today they are a nono; they make my hypertension worse and amphetamines are very proconvulsive.
I have a sezure disorder, some meds make it worse.
Posted by laima on March 1, 2007, at 10:13:05
In reply to Re: Question about if the new ADHD medication, posted by notfred on March 1, 2007, at 8:06:24
Unclear to me- I am not so versed in chemistry. Actually, pretty remedial at comprehending chemistry. Yes, I think dexedrine is supposed to be d-amphetamine- but I think that only because that is how it is listed on my pharmacy insert for generic adderall--adderall is supposed to contain dexedrine. The generic version is called "d-amphetamine, l-amphetamine salts". (I realize my method for this conclusion isn't science.)
I get the impression that for the new med, they started with dexedrine, but then altered it to metabolize in some novel way, in order to get rid of some of the effects which make amphetamines so appealing to abuse. (They attached it so some kind of enzyme?) The big innovation has got something to do with how it's metabolized, I gather. In any case, from digging around online last night, and per recollection of posts seen on babble in the past, I found that there are rumours claiming that even when taken orally as directed, this new med has near eliminated dexedrine's potential for a euphoric effect, as well as it's potential for feeling "speeded up". There are also rumours that it takes a longer time to take effect, so it's not like one can swallow it and can then feel high or speedy within the hour, no matter how much they take. The theory is that all this makes it less appealing or tempting to abuse. And as for the snortting set- they won't like it because it has zero effects until it is metabolized in the gut, and supposedly it can't get there via the nose. The wikipedia article puts it all into plainer English than Shire's press releases do. Well, yes of course, the fda is or has been demmanding stronger proof for these remarkable claims, which probably explains why it was still put in Schedule 2, but nevertheless, they did end up approving the med just very recently- like within the last week. Don't know if Shire toned down the claims, or just took them out of the literature. Or-maybe some of them were stretches. In any case, I'm sure they just wanted to hurry up and get their new product on the market. Since the drug does not even seem to be available yet, I guess we'll have to wait for candid patient reports of what it's really all about, how it feels. Sounds that it will most likely be out in spring 2007.
> dexadrine is d-amphetamine.
Posted by notfred on March 1, 2007, at 10:40:15
In reply to Re: Question about if the new ADHD medication » notfred, posted by laima on March 1, 2007, at 10:13:05
I guess we'll have to wait for candid patient reports of what it's really all about, how it feels. Sounds that it will most likely be out in spring 2007.
>
Sounds good. Thene it will be clear or not if this is another Lexapro.
Posted by laima on March 1, 2007, at 13:27:12
In reply to Re: Question about if the new ADHD medication, posted by notfred on March 1, 2007, at 10:40:15
What's the story with lexapro? I never heard it. Was it super-duper hyped up when it came out, or something like that?> Sounds good. Thene it will be clear or not if this is another Lexapro.
>
>
Posted by notfred on March 1, 2007, at 14:35:58
In reply to Re: Question about if the new ADHD medication » notfred, posted by laima on March 1, 2007, at 13:27:12
>
> What's the story with lexapro? I never heard it. Was it super-duper hyped up when it came out, or something like that?
>It is a "me too" of Celexa, just another isomer of Celexa. This board went wild and most seemed to beleive the press hype. Did not pan out as being better than Celexa.
Posted by rjlockhart on March 1, 2007, at 18:00:15
In reply to Re: Question about if the new ADHD medication, posted by notfred on March 1, 2007, at 14:35:58
Well it really just so happens that i am probaly never going back on a stimulants if i live at home, my mom will noticed me if im on them, because they do change my behavior, i went to my doctor and was prescribed Dextrostat, she found it 2 days later, in my closet. She went through the roof! screamed..... YOU NEVER EVER GOING ON THIS EVER AGAIN! You will go to Jail! please....
Well i just hope that i can learn to cope i've been coping for a year now.
Rj
Posted by Kelv on March 2, 2007, at 2:51:08
In reply to Re: Question about if the new ADHD medication, posted by rjlockhart on March 1, 2007, at 18:00:15
> Well it really just so happens that i am probaly never going back on a stimulants if i live at home, my mom will noticed me if im on them, because they do change my behavior, i went to my doctor and was prescribed Dextrostat, she found it 2 days later, in my closet. She went through the roof! screamed..... YOU NEVER EVER GOING ON THIS EVER AGAIN! You will go to Jail! please....
>
> Well i just hope that i can learn to cope i've been coping for a year now.
>
> Rj
>
>
You serve as living proof of the destructive effects of long term use of Amphetamines.
Posted by laima on March 2, 2007, at 8:46:25
In reply to Re: Question about if the new ADHD medication » rjlockhart, posted by Kelv on March 2, 2007, at 2:51:08
I wish to express my support for rj, and for his right to use the medications his doctor deems appropriate.
Posted by Dinah on March 2, 2007, at 9:40:57
In reply to Re: Question about if the new ADHD medication » rjlockhart, posted by Kelv on March 2, 2007, at 2:51:08
> You serve as living proof of the destructive effects of long term use of Amphetamines.
Please don't post anything that could lead others to feel accused or put down.
If you or others have questions about this or about posting policies in general, or are interested in alternative ways of expressing yourself, please see the FAQ:
http://www.dr-bob.org/babble/faq.html#civil
Follow-ups regarding these issues should be redirected to Psycho-Babble Administration. They, as well as replies to the above posts, should of course themselves be civil.
Dr. Bob is always free to override deputy decisions. His email is on the bottom of each page. Please feel free to email him if you believe this decision was made in error.
Dinah, acting as deputy to Dr. Bob
Posted by dbc on March 3, 2007, at 9:32:13
In reply to Please follow civility guidelines » Kelv, posted by Dinah on March 2, 2007, at 9:40:57
I wouldnt take this stuff even if it were schedule III its just a big marketing ploy. Woopty dooo kids have to swallow it instead of sticking it in their nose or whatever other orifice they put their drugs in these days.
Posted by laima on March 3, 2007, at 20:52:30
In reply to Re: Vyvanse, posted by dbc on March 3, 2007, at 9:32:13
But one might claim any new med or variant version of a med, with sincere efforts at improvments, is a mere marketing ploy. Yet, the subtle changes can be a big deal for some people!> I wouldnt take this stuff even if it were schedule III its just a big marketing ploy. Woopty dooo kids have to swallow it instead of sticking it in their nose or whatever other orifice they put their drugs in these days.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.